A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Agerelated Macular Degeneration (TALON)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brolucizumab (Primary) ; Aflibercept
Indications Wet age-related macular degeneration
Focus Registrational; Therapeutic Use
Acronyms TALON
Sponsors Novartis Pharmaceuticals

Most Recent Events

26 Nov 2022 Status changed from active, no longer recruiting to completed.
20 Oct 2022 The trial has been completed in Sweden, according to European Clinical Trials Database record.
18 Oct 2022 The trial has been completed in Germany (End Date: 9 Sep 2022) according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight